TELEFLEX Q1 FY26 earnings call TFX

Teleflex is undergoing a significant portfolio optimization, having completed the acquisition of BIOTRONIK's Vascular Intervention business in July 2025 to expand its coronary and peripheral intervention footprint. Concurrently, the company announced agreements in December 2025 to divest its acute care, interventional urology, and OEM businesses, aiming for a more focused medical technologies leader with higher revenue CAGR and greater exposure to critical care markets. The OEM divestiture is on track for a Q3 2026 close following the expiration of the Hart-Scott-Rodino waiting period in March. However, the acute care and interventional urology divestitures received a second request for information from the U.S. FTC in March, though the company still expects these transactions to close in the second half of 2026.

The company remains committed to a disciplined capital allocation strategy, intending to use the approximately $1.8 billion in net after-tax proceeds from the divestitures to fund a share repurchase program of up to $1 billion and reduce debt by $800 million. Reflecting confidence in the business and progress on the transformation plan, Teleflex now anticipates initiating opportunistic share repurchases in the open market during Q2 2026, earlier than the previously expected timing of^📎 post-divestiture completion. This action is expected to result in a meaningfully lower share count and significantly reduced interest expense starting in 2027.

In Q1 FY26, Teleflex reported $548.3 million in revenue, up 5.1% on a pro forma adjusted constant currency basis, meeting or exceeding internal expectations. The Vascular segment grew 4.8% to $236.8 million, driven by hemostatic products and central venous access. Interventional revenue increased 3% to $204.7 million, led by intraosseous, right heart, and complex catheters, though it experienced some disruption from sales force integration. The Surgical business saw strong growth of 9.9% to $106.8 million, primarily from ligation clips and favorable timing of^📎 instrument orders.

Teleflex continues to increase R&D investment, particularly in its Interventional segment. The clinical study for the Freesolve drug-eluting resorbable magnesium scaffold technology is progressing well, with enrollment for the European pivotal trial (BIOMAG-II) outpacing assumptions, targeting a late 2027 data readout. The company plans to expand its regulatory pathway for Freesolve by initiating the BIOMAG-III pivotal trial in the U.S. during 2026, with data expected around 2030. This technology aims to address the trend towards 'leaving nothing behind' in interventional cardiology.

The company announced Jason Weidman as its next President and CEO, effective June 8, highlighting his 25+ years of medical technology experience and track record in driving growth and operational execution. Additionally, Teleflex is enhancing its governance with the nomination of Michael J. Tokich to the Board and the intent to establish a new growth and operating committee. Andrew Krakauer will succeed Dr. Stephen Klasko as Chair of the Board following the upcoming Annual Stockholders Meeting, reflecting a continued focus on strong oversight and long-term performance.